| 영문 | platelet | 한글 | 혈소판 |
|---|---|---|---|
| 설명 | 골수의 거대 세포인 거대핵세포의 세포질 일부가 떨어져서 순환 혈액 중에 출현한 것으로 직경이 2~4μm의 작은 과립체이다. 혈소판은 손상을 입은 혈관의 노출된 결합 조직에 붙어 여러 물질을 분비하여 지혈 및 혈액 응고에 중요한 역할을 한다. |
||
| 영문 | test | 한글 | 검사 |
|---|---|---|---|
| 설명 | 어떤 다른 물질을 검출, 측정, 생성하기 위한 특정한 화학반응을 일으키는데 사용되는 방법. |
||
| 영문 | scratch test | 한글 | 난절법 |
|---|---|---|---|
| 설명 | 피부를 날카로운 바늘로 긁어 피부의 반응을 보는 검사로 피부 과민반응이나 알레르기를 알아보기 위한 검사이다. 바늘끝에 항원을 묻힌 뒤, 피부밑을 긁어 반응을 알아본다. 이때 항원이 아닌 대조물질(예를 들어 보통의 물)을 묻힌 바늘을 같이 반응하여 피부묘기증(dermographism) 단지 바늘의 긁힘만으로 알레르기 같은 반응을 일으키는 현상과 감별해야 한다. 난청, 청력소실(hearing loss) 청각이 저하 또는 상실된 상태. 원인과 정도는 여러 가지인데, 난청은 그 정도가 가장 심한 상태이다. 청각의 전도경로에 장애가 있을 때 난청이 일어나고, 그 병터가 외이도나 중이에 있는 것을 전음난청, 내이에 있는 것을 감음 난청이라 하여 구분한다. 또 병터의 자리를 명시하여 중이성 난청이나 미로성 난청 등으로 세분하기도 한다. |
||
| 영문 | stool guaiac test | 한글 | 대변 구아이악 검사 |
|---|---|---|---|
| 설명 | 대변내에 있을 수 있는 잠혈(눈에 보이지 않는 출혈)유무를 검사하는 방법으로, 혈구내의 heme peroxidase에 의해 guaiac이 산화되는 반응을 이용하여 측정한다. 방법은 3일간에 걸쳐 한 변에서 2군데씩 채취하여 검사한다. 위양성 반응(거짓으로 혈액이 있다고 나타나는 반응)은 식물 과산화효소를 함유하고 있는 홍당무의 섭취나 혈구 성분을 함유하고 있는 고기 섭취 등에서 나타날 수 있으며, 위음성 반응(실제로 혈액은 있지만, 혈액이 없다고 나타나는 반응)은 환원력을 가지고 있는 비타민 C의 복용시 나타날 수 있다. 특히 위양성 반응이 매우 흔하다. |
||
| 영문 | Rorschach Test | 한글 | 로르샤하 검사 |
|---|---|---|---|
| 설명 | 사고장애와 정서장애에 민감한 투사검사(projective test). 검은색과 몇가지 색으로 이루어진 잉크얼룩같은 도형이 그려진 10개의 카드를 이용한다. 피검자에게 카드를 보이고 본 것에 대해 말하도록 한다. 다음에는 얼룩의 어느 위치가 피검자가 말한 지각대상을 암시하는지 찾도록 한다. 피검자의 답변을 분석하면 그의 사고와 정서상태에 대한 정보를 얻을 수 있다. |
||
| PAT | Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili... |
|---|---|
| PA | panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'... |
| PAFI | platelet-aggregation factor inhibitor |
| SPA | salt-poor albumin; sheep pulmonary adenomatosis; sperm penetration assay; spinal progressive amyotro... |
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| PAT | Platelet aggregation test |
|---|---|
| PA | Platelet aggregation |
| RIPA | Ristocetin induced platelet aggregation |
| SIPA | Sh ear-induced platelet aggregation |
| SPA | Spontaneous Platelet Aggregation |
| platelet aggregation test | A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin). (05 Mar 2000) |
|---|
| platelet aggregation | The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus. (12 Dec 1998) |
|---|---|
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
| aggregation | Massing of materials together as in clumping. (18 Nov 1997) |
| receptor aggregation | Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell. (12 Dec 1998) |
| cell aggregation | The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type. (12 Dec 1998) |
| erythrocyte aggregation | Aggregation of erythrocytes probably resulting from changes in the negative surface charge (zeta potential) of the cells caused by the dielectric effect of proteins in the surrounding plasma, especially asymmetric macromolecules like fibrinogen and gamma-globulin. (12 Dec 1998) |
| erythrocyte aggregation, intravascular | The massing or clumping of erythrocytes in intact blood vessels in response to injury or in certain diseases, interfering with adequate blood flow. It is also called sludging of blood and intravascular agglutination. (12 Dec 1998) |
| familial aggregation | <genetics> The occurrence of a trait in more members of a family than can be readily accounted for by chance; presumptive but not cogent evidence of the operation of genetic factors. (05 Mar 2000) |
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| medication, anti-platelet | Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| platelet | <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels. Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation. Synonym: thrombocytes. (09 Oct 1997) |
| platelet-activating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|